KRMN — Karman Space & Defense: Down 58% from Peak, Is the Market Mispricing a Hypergrowth Defense Compounder?

Why I'm Looking at This

Karman Holdings went public in February 2025 and almost immediately became one of the most exciting stories in the aerospace and defense small-cap space. By January 2026, it was trading at $118. Today, it's at $49.50 — a 58% collapse from peak — yet the underlying business just posted its best quarter in company history. That kind of divergence between price and fundamentals is worth examining very carefully.

What Does Karman Actually Do?

Karman Space & Defense manufactures mission-critical, high-complexity structures for the U.S. defense and commercial space ecosystem. Its four end markets are:

• Hypersonics & Strategic Missile Defense — warhead delivery and interceptor components
• Tactical Missiles & Integrated Defense — subsystems for priority munitions programs
• Space & Launch — payload fairings, interstage adapters, and propulsion structures for virtually all major U.S. launch providers
• Maritime Defense Systems (newly added in 2026)

The company is not a contractor that wins and rebids. It designs and manufactures highly engineered, sole-source components that are qualified years ahead of production. Once Karman's part is designed into a missile or rocket, switching suppliers mid-program is prohibitively expensive and disruptive. That is a meaningful moat for a company of this size.

The Fundamental Picture (Q1 FY2026 — Most Recent Quarter)

The numbers tell a striking story:

Revenue has compounded at 28% CAGR from 2022 to 2025, and the growth is now accelerating, not decelerating. The company raised its full-year 2026 guidance after Q1: $720–$735M in revenue and $208.5–$219.5M in adjusted EBITDA — implying roughly 54% and 47% year-over-year growth, respectively. Management notes that 90% of raised guidance is already covered by existing backlog converting this year.

The backlog exceeding $1 billion, up 61% year-over-year, is the single most important data point in this story. It represents 1.4x forward annual revenue and provides exceptional near-term visibility.

Why Is the Stock Down 58%?

Three reasons, none of them new:

1. Leverage. The company carries approximately $770M in term loan debt (SOFR + 2.75%), with cash of $73.8M as of March 31, 2026. Net debt of ~$696M is significant relative to current EBITDA, though it is declining rapidly as earnings ramp.
2. EPS misses vs. consensus. In Q4 2025, Karman beat revenue but missed adjusted EPS by $0.04. In Q1 2026, it beat revenue estimates but adjusted EPS of $0.11 came in slightly below some estimates. In a high-multiple stock, any shortfall triggers a disproportionate selldown.
3. Valuation reset from euphoria. The stock was pricing in near-perfection at $118. The market has de-rated the stock sharply on the combination of leverage, modest EPS misses, and broader risk-off sentiment in high-multiple industrials.

None of these concerns have materially changed the underlying business trajectory.

Fair Value Analysis

Method 1: Simply Wall St DCF (FCFE, 2-Stage)

The Simply Wall St DCF model, which runs daily, placed Karman's intrinsic value at approximately $60.35 per share as of early May 2026, when the stock was trading around $63 (implying 4.7% overvaluation at that time). With the stock now at $49.50 — roughly 18% below that estimate — the same model now implies meaningful undervaluation, all else equal.

The model assumes free cash flow reaching approximately $59.6M in 2026 and $351M by 2030, discounted at a standard risk-adjusted rate. The key swing factor: FCF conversion is currently negative (LTM FCF was –$44.6M) due to heavy acquisition integration capex. As integration winds down and revenue scales, FCF should inflect sharply. Analysts project FCF turning robustly positive across 2026–2028.

Base case intrinsic value (SWS model): ~$60

Method 2: EV/EBITDA Relative to Aerospace Peers

Premium aerospace and defense manufacturers with high engineering content and long-term government contracts — think TransDigm, HEICO, and Curtiss-Wright — trade in the range of 20–30x EV/EBITDA. Karman is earlier-stage with higher leverage, so a discount is warranted.

FY2027E EBITDA of $310M assumes ~45% growth from the 2026 guidance midpoint, consistent with management's stated growth trajectory and analyst consensus revisions.

Shares outstanding: ~132.5M.

Method 3: Analyst Consensus Price Target

Eleven analysts cover the stock. The consensus 12-month price target is $105.60, with a range of $100 (KeyBanc, Overweight) to $114 (Piper Sandler, Overweight). Both firms reduced targets after Q1 citing higher near-term integration costs, but both reiterated conviction in the long-term thesis.

The consensus implies +113% upside from today's price.

My Fair Value Range

Synthesizing the three methods above, and acknowledging the leverage risk as a real constraint on valuation multiples:

At $49.50, the stock is trading near the lower end of my base case, offering 2:1+ risk/reward if guidance is met.

The Key Risks

1. Debt burden. $770M in floating-rate debt is the biggest risk to the equity story. If SOFR stays elevated and EBITDA disappoints, interest coverage could tighten materially. Debt/EBITDA is currently ~3.6x on 2026E EBITDA — manageable, but not comfortable.

2. Customer concentration. Two customers represented 25.6% and 11.6% of Q1 2026 revenue. Program delays or budget cuts from either would have outsized impact.

3. Acquisition integration. Karman has completed six acquisitions in roughly 18 months. Integration risk is real, and the modest EPS misses in Q4 2025 and Q1 2026 suggest some friction. If Seemann Composites or MSC underperforms expectations, it could weigh on margins.

4. Defense budget uncertainty. Despite broad bipartisan support for missile defense and space investment, any pivot in U.S. government spending priorities could slow backlog conversion.

Why I Think the Bull Case Is More Likely Than Not

The bearish case requires either a macro dislocation in defense spending (unlikely given the current geopolitical environment) or a material operational failure in integration. Neither is occurring. The business is:

• Growing revenue at 50%+ YoY
• Expanding gross margins to 42%
• Sitting on a $1B+ backlog at record levels
• Generating positive net income for the first time
• Receiving multi-year contingent demand commitments from four key defense and space customers with total potential value exceeding $1 billion

This is not a story of a company in distress that the market is correctly marking down. It is a hypergrowth defense compounder that ran too far, too fast, got punished for modest EPS misses, and is now pricing in a much more pessimistic scenario than the fundamentals support.

My Position

I view $49–55 as an attractive entry zone for investors with a 12–24 month time horizon and tolerance for leverage risk. The SWS DCF model puts fair value at approximately $60, the EV/EBITDA base case lands near $55–65, and 11 analysts with deep defense sector expertise have an average 12-month target of $105.60.

The margin of safety is not enormous at current prices — the bear case is a real $30–35 scenario. But the probability-weighted expected return, given the backlog visibility and growth trajectory, appears compelling.

Summary Scorecard

Overall: 38/50 — Near-Term Catalyst + Emerging Long-Term Compounder

This post represents my personal fair value analysis and is not financial advice. I hold no position in KRMN at the time of writing. Always do your own due diligence, review SEC filings directly at EDGAR, and consider consulting a licensed financial advisor before making any investment decision. Analyst price targets may reflect conflicts of interest (FINRA).